Literature DB >> 25389802

Review: Influence of ART on HIV genetics.

Francesco R Simonetti1, Mary F Kearney.   

Abstract

PURPOSE OF REVIEW: HIV genetic diversity poses major challenges for the prevention, control, and cure of infection. Characterizing the diversity and evolution of HIV populations within the host provides insights into the mechanisms of HIV persistence during antiretroviral therapy (ART). This review describes the HIV diversity within patients, how it is affected by suppressive ART, and makes a case for early treatment after HIV infection. RECENT
FINDINGS: HIV evolution is effectively halted by ART. However, cells that were infected prior to initiating therapy can proliferate to very high numbers both before and during treatment. Such clonal expansions result in the persistence of integrated proviruses despite therapy. These expanding proviruses have been shown to be a source for residual viremia during ART, and they may be a source for viral rebound after interrupting ART.
SUMMARY: Plasma HIV RNA shows no evidence for evolution during ART, suggesting that HIV persistence is not driven by low-level, ongoing replication. The emergence of identical viral sequences observed in both HIV RNA and DNA is likely due to proliferation of infected cells. Early treatment restricts the viral population and reduces the number of variants that must be targeted for future therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25389802      PMCID: PMC4392820          DOI: 10.1097/COH.0000000000000120

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  56 in total

1.  HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.

Authors:  Helene Mens; Mary Kearney; Ann Wiegand; Wei Shao; Kristian Schønning; Jan Gerstoft; Niels Obel; Frank Maldarelli; John W Mellors; Thomas Benfield; John M Coffin
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartments.

Authors:  Hiromi Imamichi; Gerald Degray; Robin L Dewar; Peter Mannon; Michael Yao; Cheryl Chairez; Irini Sereti; Joseph A Kovacs
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

3.  Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Sara Gianella; Elizabeth Sinclair; Lorrie Epling; Qingsheng Li; Lijie Duan; Alex L M Choi; Valerie Girling; Terence Ho; Peilin Li; Katsuya Fujimoto; Harry Lampiris; C Bradley Hare; Mark Pandori; Ashley T Haase; Huldrych F Günthard; Marek Fischer; Amandeep K Shergill; Kenneth McQuaid; Diane V Havlir; Joseph K Wong
Journal:  J Infect Dis       Date:  2010-10-12       Impact factor: 5.226

4.  Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

Authors:  D McMahon; J Jones; A Wiegand; S J Gange; M Kearney; S Palmer; S McNulty; J A Metcalf; E Acosta; C Rehm; J M Coffin; J W Mellors; F Maldarelli
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

5.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Amandeep K Shergill; Kenneth McQuaid; Sara Gianella; Harry Lampiris; C Bradley Hare; Mark Pandori; Elizabeth Sinclair; Huldrych F Günthard; Marek Fischer; Joseph K Wong; Diane V Havlir
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

6.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.

Authors:  J B Dinoso; S Y Kim; A M Wiegand; S E Palmer; S J Gange; L Cranmer; A O'Shea; M Callender; A Spivak; T Brennan; M F Kearney; M A Proschan; J M Mican; C A Rehm; J M Coffin; J W Mellors; R F Siliciano; F Maldarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

7.  Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus.

Authors:  Marta E Bull; Gerald H Learn; Scott McElhone; Jane Hitti; David Lockhart; Sarah Holte; Joan Dragavon; Robert W Coombs; James I Mullins; Lisa M Frenkel
Journal:  J Virol       Date:  2009-04-01       Impact factor: 5.103

8.  Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors.

Authors:  Cristina Cellerai; Alexandre Harari; Hans Stauss; Sabine Yerly; Anna-Maria Geretti; Anne Carroll; Thynn Yee; Jonathan Ainsworth; Ian Williams; John Sweeney; Andrew Freedman; Margaret Johnson; Giuseppe Pantaleo; Sabine Kinloch-de Loes
Journal:  PLoS One       Date:  2011-04-05       Impact factor: 3.240

9.  The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

Authors:  Rajesh T Gandhi; Lu Zheng; Ronald J Bosch; Ellen S Chan; David M Margolis; Sarah Read; Beatrice Kallungal; Sarah Palmer; Kathy Medvik; Michael M Lederman; Nadia Alatrakchi; Jeffrey M Jacobson; Ann Wiegand; Mary Kearney; John M Coffin; John W Mellors; Joseph J Eron
Journal:  PLoS Med       Date:  2010-08-10       Impact factor: 11.069

10.  Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations.

Authors:  Marta Bull; Gerald Learn; Indira Genowati; Jennifer McKernan; Jane Hitti; David Lockhart; Kenneth Tapia; Sarah Holte; Joan Dragavon; Robert Coombs; James Mullins; Lisa Frenkel
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

View more
  9 in total

1.  Accidental Father-to-Son HIV-1 Transmission During the Seroconversion Period.

Authors:  Ifeanyi Ezeonwumelu; Inês Bártolo; Francisco Martin; Ana Abecasis; Teresa Campos; Ethan O Romero-Severson; Thomas Leitner; Nuno Taveira
Journal:  AIDS Res Hum Retroviruses       Date:  2018-09-20       Impact factor: 2.205

2.  Retroviral integrase: Structure, mechanism, and inhibition.

Authors:  Dario Oliveira Passos; Min Li; Robert Craigie; Dmitry Lyumkis
Journal:  Enzymes       Date:  2021-08-23

3.  Evaluation of a Novel In-house HIV-1 Genotype Drug Resistance Assay using Clinical Samples in China.

Authors:  Peijie Gao; Fengting Yu; Xiaozhen Yang; Dan Li; Yalun Shi; Yan Wang; Fujie Zhang
Journal:  Curr HIV Res       Date:  2022       Impact factor: 1.341

Review 4.  The role of HIV integration in viral persistence: no more whistling past the proviral graveyard.

Authors:  Frank Maldarelli
Journal:  J Clin Invest       Date:  2016-02-01       Impact factor: 14.808

5.  Have Cells Harboring the HIV Reservoir Been Immunoedited?

Authors:  Szu-Han Huang; Chase D McCann; Talia M Mota; Chao Wang; Steven M Lipkin; R Brad Jones
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

6.  Molecular transmission networks and pre-treatment drug resistance among individuals with acute HIV-1 infection in Baoding, China.

Authors:  Penghui Shi; Zhixia Chen; Juan Meng; Miaomiao Su; Xuegang Yang; Weiguang Fan; Haoxi Shi; Ying Gao; Xinli Lu
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

7.  Genotypic and Phenotypic Diversity of the Replication-Competent HIV Reservoir in Treated Patients.

Authors:  Alexandre Nicolas; Julie Migraine; Jacques Dutrieux; Maud Salmona; Alexandra Tauzin; Atsuko Hachiya; Jérôme Estaquier; Jean-Michel Molina; François Clavel; Allan J Hance; Fabrizio Mammano
Journal:  Microbiol Spectr       Date:  2022-06-30

8.  Weakest-Link Dynamics Predict Apparent Antibiotic Interactions in a Model Cross-Feeding Community.

Authors:  Elizabeth M Adamowicz; William R Harcombe
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

9.  The Body Fat Percentage Rather Than the BMI Is Associated with the CD4 Count among HIV Positive Japanese Individuals.

Authors:  Kumiko Shoji; Michinori Shirano; Mitsuru Konishi; Yuko Toyoshima; Miyuki Matsumoto; Tetsushi Goto; Yu Kasamatsu; Yuji Ichida; Yasuo Kagawa; Terue Kawabata; Hiromitsu Ogata; Daiki Habu
Journal:  Nutrients       Date:  2022-01-18       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.